According to the research report titled ‘Europe Cell Line Development Market Size By Product, Source, Cell Line, Application, Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2018 – 2024’, available with Market Study Report, Europe cell line development market is expected to surpass USD 2.1 billion by the year 2024.
 

Growing demand for monoclonal antibodies and vaccines for treating anti-inflammatory disease, autoimmune disorders, and cancer is driving the cell line development market in Europe. Rising adoption of advanced cell line development products, escalating healthcare expenditure and technological improvements in biotechnology are further aiding the market expansion. Availability of remote screening methods, improved expression systems, preference for disposable equipment, and access to enriched medias for improving cell line development practices are also stimulating the industry outlook. However, strict regulatory scenario and rising concerns regarding stem cell research may hinder the overall market expansion.
 

By product type, the report states that reagents & media segment held 53.6% share in 2017 and presumed to expand substantially during the estimated timeframe. Rising adoption of reagents & media for drug discovery, research, and tissue engineering applications is fueling the segmental growth.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2505898/
 

In terms of source type, mammalian cell structures segment was worth USD 650.8 million in 2017 and is expected to grow significantly during the study period. Increasing usage of mammalian cell cultures for developing complex biotherapeutic proteins is favoring the industry landscape. Mammalian cell cultures are extensively utilized in vaccine production for treatment of rubella, mumps, and the other diseases.
 

As per cell type, recombinant cell segment is set to record a growth rate of 12.5% through 2024, primarily due to increasing application of rDNA technology to develop immunobiologics, synthetic hormones, enzymes, and other anti-cancer drugs.
 

Considering the geographical landscape, the report cites that Germany cell line development industry is poised to acquire considerable returns during the projected timeframe, owing to increased pervasiveness of various diseases in the country. There has been a rise in adoption of monoclonal antibodies and vaccines. Surging investments towards R&D activities along with advancements in biotechnology industry are promoting the market outlook in Germany.
 

The established players of Europe cell line development industry are Progenitor Cell Therapy, GVK BIO, Sigma-Aldrich (Merck), The European Collection of Cell Cultures, Thermo Fisher Scientific, GE Healthcare, WuXi AppTec, Samsung Biologics, Lonza Group, Sartorius, and Selexis.